ArticleFrontiers in cardiovascular medicine2025
Effect of combined dexmedetomidine with ropivacaine in transversus thoracis plane block on surgical stress response during cardiopulmonary bypass surgery: a randomized controlled trial.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine how patients having open heart surgery under cardiopulmonary bypass (CPB) react to surgical stress following bilateral transversus thoracis plane (TTP) block with ropivacaine improved by dexmedetomidine (DEX). Methods: Three groups of sixty patients (26M/34F, ASA II-III, 18-65 years old) slated for elective CPB heart surgery were randomly assigned: general anesthesia alone (Group C), TTP (ropivacaine) combined with general anesthesia group (Group R), or TTP (ropivacaine + DEX) combined with general anesthesia group (Group RD). Primary outcomes measured serum cortisol levels at five perioperative phases, while the secondary outcomes included glucose/C-reactive protein (CRP) levels, Numeric Rating Scale (NRS) pain scores postextubation, 48-hr sufentanil consumption, patient-controlled analgesia (PCA) demand frequency, rescue analgesia rates, mechanical ventilation duration, ICU stay, and complications. Results: At 24 h postoperatively, RD and R groups exhibited statistical lower serum cortisol levels compared to controls ( Conclusion: DEX-enhanced TTP blockade may contribute to attenuating the stress response, optimizing analgesia, and improving early postoperative recovery parameters in CPB cardiac surgery through opioid-sparing mechanisms and sympatholytic effects, demonstrating clinical viability within Enhanced Recovery After Surgery (ERAS) protocols. Clinical Trial Registration: https://www.chictr.org.cn/index.html, identifier ChiCTR2400085899.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.